Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Fig. 1

Treatment with dasatinib reduces SF-secreted levels of inflammatory proteins in vitro. Tg197 synovial fibroblast-secreted hTNF (a), CCL20 (b), CCL5 (c) levels following a 48 h treatment with Infliximab (10 nM), dasatinib (100 nM) or bosutinib (100 nM). (* p-value < 0.05; ** p-value < 0.01; *** p-value ≤ 0.0001). All data are shown as mean ± SEM and all comparisons were made against vehicle

Back to article page